Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study
Credit: MD Anderson Cancer Center A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown...










